Search research articles
Contact Us
Filters
Showing results (11-20 of 82) with videos related to
Page
of 9
Sort By:
The Journal of Experimental Medicine
|
August 4, 1999
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
Z Wang, F M Marincola, L Rivoltini, et al.
Cancer Immunology, Immunotherapy : CII
|
June 1, 1993
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells
P A Ruffini, L Rivoltini, A Silvani, et al.
International Journal of Cancer
|
October 15, 1988
Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx)
C Gambacorti-Passerini, L Rivoltini, R Supino, et al.
Journal of Cellular Physiology
|
February 1, 2000
T-cell recognition of melanoma-associated antigens
C Castelli, L Rivoltini, G Andreola, et al.
International Journal of Cancer
|
October 15, 1990
Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line
L Rivoltini, M P Colombo, R Supino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 23, 2006
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
G Parmiani, C Castelli, L Pilla, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1996
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells
F M Marincola, L Rivoltini, M L Salgaller, et al.
Cancer Metastasis Reviews
|
December 1, 1988
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK)
C Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Tumori
|
December 31, 1990
Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2
M Squadrelli-Saraceno, L Rivoltini, G Cantù, et al.
The Journal of Clinical Investigation
|
June 24, 1998
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma
D J Hicklin, Z Wang, F Arienti, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 82) with videos related to
Sort By:
Page
of 9
The Journal of Experimental Medicine
|
August 4, 1999
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
Z Wang, F M Marincola, L Rivoltini, et al.
Cancer Immunology, Immunotherapy : CII
|
June 1, 1993
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells
P A Ruffini, L Rivoltini, A Silvani, et al.
International Journal of Cancer
|
October 15, 1988
Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx)
C Gambacorti-Passerini, L Rivoltini, R Supino, et al.
Journal of Cellular Physiology
|
February 1, 2000
T-cell recognition of melanoma-associated antigens
C Castelli, L Rivoltini, G Andreola, et al.
International Journal of Cancer
|
October 15, 1990
Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line
L Rivoltini, M P Colombo, R Supino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 23, 2006
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
G Parmiani, C Castelli, L Pilla, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1996
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells
F M Marincola, L Rivoltini, M L Salgaller, et al.
Cancer Metastasis Reviews
|
December 1, 1988
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK)
C Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Tumori
|
December 31, 1990
Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2
M Squadrelli-Saraceno, L Rivoltini, G Cantù, et al.
The Journal of Clinical Investigation
|
June 24, 1998
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma
D J Hicklin, Z Wang, F Arienti, et al.
Page
of 9